Abstract
In 2016 and 2017, monoclonal antibodies targeting PD-L1, including atezolizumab, durvalumab, and avelumab, were approved by the FDA for the treatment ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
